Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA StudyMarina Elena Cazzaniga, Giorgio Mustacchi, Monica Giordano et al.|Cancers|2023Cited by 2
Choice of treatment and adherence to international ESO-ESMO (ABC) guidelines in HR+/HER2-ve metastatic breast cancer (MBC) patients (pts).Marina Elena Cazzaniga, Giorgio Mustacchi, Emanuela Romagnoli et al.|Journal of Clinical Oncology|2017Cited by 1
The role of taxanes in HR+ve/HER2-ve metastatic breast cancer (MBC) patients (pts) from adjuvant to metastatic setting in the clinical practice: Results from GIM13-AMBRA study.Giorgio Mustacchi, Marina Elena Cazzaniga, Emanuela Romagnoli et al.|Journal of Clinical Oncology|2017Cited by 1
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2– Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA StudiesMarina Elena Cazzaniga, P. Pronzato, Claudio Verusio et al.|Breast Care|2019Cited by 1
Characteristics of disease activity able to identify risk categories and probability to respond to first-line endocrine therapy (ET) in HR+ve/HER2-ve metastatic breast cancer (MBC) patients (pts): Dream or reality? Evaluation of a composite risk score in a subgroup population of the GIM 13-AMBRA study.Giorgio Mustacchi, Marina Elena Cazzaniga, Monica Giordano et al.|Journal of Clinical Oncology|2017Cited by 0